Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06434909
PHASE2

CYTALUX™for the Intraoperative Imaging of Prostate Cancer

Sponsor: Indiana University

View on ClinicalTrials.gov

Summary

This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.)

Official title: An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX™ (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

9

Start Date

2024-09-19

Completion Date

2025-09-04

Last Updated

2026-06-01

Healthy Volunteers

No

Conditions

Interventions

DRUG

Cytalux™ (pafolacianine) for fluorescent imaging

Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status. This is used in conjunction with appropriate imaging system.

PROCEDURE

Image Guided Surgery

prostatectomy using appropriate imaging system

Locations (3)

IU Health Joe and Shelly Schwarz Cancer Center

Carmel, Indiana, United States

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, United States

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States